Lung Transplantation Clinical Trial
Official title:
Pharmacokinetic Profile of Inhaled Liposomal Amphotericin B in Lung Transplant Recipients - Ambisome Study
The purpose of this study is to determine the steady state concentrations of inhaled liposomal amphotericin B (Ambisome®) in lung transplant recipients via aerosolized nebulization.
Each subject will receive 1 mg/kg/day of inhaled Ambisome® for four days prior to the BAL
(bronchoalveolar lavage) procedure. The dosage of 1 mg/kg was calculated by extrapolating
the dosage of 1.6 mg/kg for the surface area of the rat lung to the human lung surface area
in a 60 kg individual.
All four doses will be given in the presence of a physician and/or study coordinator. The
forty eight subjects will be randomized such that six subjects undergo the BAL at 1, 12, 24,
48, 72, 96, 120, and 168 hours after the last dose of inhaled Liposomal amphotericin B
(AmBisome®).
A blood sample (5 ml) will be obtained prior to the fourth dose of study medication and on
the day of bronchoscopy (pseudo steady state trough). Concentrations of amphotericin in the
serum, and bronchoalveolar lavage will be measured at pre-specified intervals after
administration of liposomal amphotericin B (AmBisome®) in lung transplant recipients
undergoing routine bronchoscopy as mentioned earlier.
A 5 ml blood sample will be recovered at the time of bronchoscopy for the purpose of
determination of serum amphotericin B concentration and for the determination of serum urea
concentration.
The bronchoscopy and bronchoalveolar lavage of subjects is done as a part of routine
transplant care. Subjects will be followed for the follow-up of results of bronchoscopy at
the interval deemed necessary by their transplant pulmonologist. The samples (blood and
bronchoalveolar samples) will be under the control of the principal investigator of this
research project. To protect confidentiality, all personal identifiers (i.e., name, social
security number, and birth date) will be removed (de-identified) and replaced with a
specific code number. The information linking these code numbers to the corresponding
subjects' identities will be kept in a separate, secure location (ID lab at 8th floor Scaife
Hall). The investigators on this study will keep the samples indefinitely. Samples may be
given to investigators outside of UPMC or may be utilized in future studies about infectious
diseases. If the samples are given to investigators not associated with this study, the
samples will be provided without any identifiers. No genetic testing will be done on the
samples obtained.
;
Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02581111 -
Naloxone for Optimizing Hypoxemia Of Lung Donors
|
Phase 2/Phase 3 | |
| Recruiting |
NCT02177916 -
Patient Education Study to Determine Knowledge Acquisition in Patients Preparing to Undergo Lung Transplantation
|
N/A | |
| Not yet recruiting |
NCT01394835 -
Safety and Efficacy of Inhaled Alpha-1 Antitrypsin in Preventing Bronchiolitis Obliterable Syndrome in Lung Transplant Recipients
|
Phase 2 | |
| Not yet recruiting |
NCT01162148 -
Pulmonary Rehabilitation and Inspiratory Muscle Training (IMT) for Patients Following Lung Transplantation
|
N/A | |
| Completed |
NCT01204970 -
Confocal Laser Micro-endoscopy in Chronic Obstructive Pulmonary Disease (COPD) and Lung Transplant Recipients
|
N/A | |
| Active, not recruiting |
NCT00980967 -
Predictive Factors for Chronic Rejection in Lung Transplant Recipients: COLT Study
|
N/A | |
| Completed |
NCT00531921 -
Effects of Donor and Recipient Genetic Expression on Heart, Lung, Liver, or Kidney Transplant Survival
|
N/A | |
| Recruiting |
NCT00163696 -
Multi Breath Nitrogen Washout (MBNW) as a Measure of Small Airway Function in Patients With Respiratory Disease
|
N/A | |
| Completed |
NCT00177684 -
Pharmacokinetic Profiles of Inhaled Lipid Complex Amphotericin B (Abelcet ®)
|
Phase 3 | |
| Completed |
NCT00163891 -
Comparison of Two Chest Physiotherapy Protocols in Lung Transplant Recipients
|
N/A | |
| Completed |
NCT03668483 -
Relation Between Muscle Strength With Exercise Capacity and Dyspnea in LTx
|
N/A | |
| Not yet recruiting |
NCT02855372 -
Impact of the Age Difference Between the Donor and Recipient on the Morbidity and Mortality After Lung Transplantation. Study on a National Multicenter Cohort (COLT)
|
N/A | |
| Completed |
NCT01212406 -
Vitamin D in Bronchiolitis Obliterans Syndrome
|
Phase 4 | |
| Completed |
NCT01211509 -
Montelukast in Bronchiolitis Obliterans Syndrome
|
Phase 4 | |
| Not yet recruiting |
NCT00808600 -
Empowerment of Lung and Heart-lung Transplant Patients
|
N/A | |
| Completed |
NCT00553397 -
Live Lung Donor Retrospective Study
|
N/A | |
| Completed |
NCT00402805 -
Improving the Humoral Response to Influenza Vaccine in Lung Transplant Recipients by an Intradermal Strategy
|
Phase 4 | |
| Completed |
NCT00701922 -
Surveillance Study of Viral Infections Following Lung Transplantation
|
N/A | |
| Terminated |
NCT00235651 -
Abelcet Radiotagging Protocol: Inhaled Lipid Complex Abelcet® in Lung Transplant Recipients
|
Phase 3 | |
| Active, not recruiting |
NCT02936505 -
Clinical Study Evaluating Two Treatment Protocols for Immunosuppressive Drugs. Looking at 3-year Incidence of CLAD.
|
N/A |